CureDM Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2M

CureDM General Information

Description

Operator of a biopharmaceutical company intended to develop new therapies that may prevent, ameliorate or reverse diabetes. The company has discovered and is developing a novel human peptide associated with the regeneration of insulin-producing islets within the pancreas, thereby enabling customers the discontinuation of insulin.

Contact Information

Website
www.curedm.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1201 North Market Street
  • Suite 701
  • Wilmington, DE 19801
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • 1201 North Market Street
  • Suite 701
  • Wilmington, DE 19801
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CureDM Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 12-Feb-2018 $2M Completed Generating Revenue
5. Later Stage VC (Series C2) 10-Aug-2009 Completed Generating Revenue
4. Debt - General 28-Jan-2009 Completed Generating Revenue
3. Debt - General 27-Feb-2008 Completed Startup
2. Early Stage VC (Series B) 30-Nov-2006 $2.5M $2.79M Completed Startup
1. Early Stage VC (Series A) 22-Nov-2005 $290K $290K Completed Startup
To view CureDM’s complete valuation and funding history, request access »

CureDM Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C2
Series C1
Series B 2,469,711 $0.001000 $1.24 $1.24 1x $0.78 13.55%
Series A 1,463,483 $0.001000 $0.5 $0.5 1x $0.48 5.22%
To view CureDM’s complete cap table history, request access »

CureDM Patents

CureDM Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20110082080-A1 Compositions and methods of using the human proislet peptide receptor Inactive 12-Oct-2007
WO-2009049222-A1 Compositions and methods of using the human proislet peptide receptor Inactive 12-Oct-2007
JP-2014028825-A Composition and method of using pancreatic islet formation promoting peptide and analog thereof Active 30-Aug-2007
AU-2008292913-A1 Compositions and methods of using proislet peptides and analogs thereof Active 30-Aug-2007
AU-2008292913-B2 Compositions and methods of using proislet peptides and analogs thereof Inactive 30-Aug-2007 C07K14/47
To view CureDM’s complete patent history, request access »

CureDM Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CureDM Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Calvert Research Venture Capital Minority
Scientific Health Development Venture Capital Minority
To view CureDM’s complete investors history, request access »

CureDM FAQs

  • When was CureDM founded?

    CureDM was founded in 2004.

  • Where is CureDM headquartered?

    CureDM is headquartered in Wilmington, DE.

  • What is the size of CureDM?

    CureDM has 3 total employees.

  • What industry is CureDM in?

    CureDM’s primary industry is Drug Discovery.

  • Is CureDM a private or public company?

    CureDM is a Private company.

  • What is the current valuation of CureDM?

    The current valuation of CureDM is .

  • What is CureDM’s current revenue?

    The current revenue for CureDM is .

  • How much funding has CureDM raised over time?

    CureDM has raised $6.36M.

  • Who are CureDM’s investors?

    Calvert Research and Scientific Health Development have invested in CureDM.

  • When was CureDM acquired?

    CureDM was acquired on 12-Feb-2018.

  • Who acquired CureDM?

    CureDM was acquired by Boston Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process